Gilead (GILD) Up as Twice-Yearly HIV Shot Prevents Infection

Gilead Sciences, Inc. (GILD) announced upbeat top-line results from an interim analysis of its late-stage study PURPOSE 1.PURPOSE 1 is a phase III, double-blind, randomized study evaluating the safety and efficacy of twice-yearly, subcutaneous lenacapavir for pre-exposure prophylaxis (PrEP) and once-daily oral Descovy (emtricitabine 200mg and tenofovir alafenamide 25mg; F/TAF) in more than 5,300 cisgender women and adolescent girls aged 16-25 years across 25 sites in South Africa and three sites in Uganda.B ...